IP Library › Granted Patent US 12,611,408
Granted Patent B2
US 12,611,408 · App. 17/250,123 · Granted Apr 28, 2026

Methods for treating nail brittleness, fragility, or pitting

Inventor: Lars Brichta (Brooklyn, NY)
Assignee: Chemistry RX
A61K31/519A61K9/127A61K31/122A61K31/497A61K31/4985A61K31/506A61K31/529A61K31/5377A61K31/541A61K31/5575A61K31/58A61K31/585A61K31/655A61K31/7076A61K35/62A61K47/20A61P17/00A61P17/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,611,408
App. No.
17/250,123
Granted
Apr 28, 2026
Kind
B2
Abstract

Compositions and methods for treating hair loss and/or nail brittleness, fragility, and pitting, particularly in pediatric patients, using topically administered JAK/STAT inhibitors and one or more penetration enhancer are described herein.

Claims (11)

1 . A method for treating nail brittleness, fragility, or pitting comprising administering a topical composition to a subject in need thereof, wherein the composition comprises a JAK/STAT inhibitor, a base, a penetration enhancer, and an emulsifying agent, and wherein

the JAK/STAT inhibitor is about 2% (w/w) of the total composition;

the penetration enhancer is dimethyl sulphoxide (DMSO) and about 20% (w/w) of the total composition;

the base is about 65% (w/w) to about 75% (w/w) of the total composition and is selected from the group consisting of white petrolatum, white petrolatum USP, mineral jelly, petroleum jelly, yellow petrolatum, yellow soft paraffin, white soft paraffin, fats, waxes, sterols, fat-soluble vitamins, monoglycerides, diglycerides, triglycerides, liposomal base, and combinations thereof; and

the emulsifying agent is about 8% (w/w) of the total composition.

2 . The method of claim 1 , wherein the subject has a disorder selected from the group consisting of alopecia areata, alopecia totalis, alopecia universalis, vitiligo, graft versus host disease, telogen effluvium, tinea capitis (dermatophytosis), hypotrichosis, hereditary hypotrichosis simplex, frontal fibrosing alopecia, cicatricial alopecia, lichen planopilaris, ring alopecia, and chemotherapy induced alopecia.

3 . The method of claim 1 , wherein the JAK/STAT inhibitor is selected from the group consisting of ruxolitinib, tofacitinib, fedratinib, lestaurtinib, fludarabine, epigallocatechin-3-gallate (EGCG), baricitinib, momelotinib, pacritinib, peficitinib, decernmotinib, filgotinib, gandotinib, cerdulatinib, hyperforin, and pharmaceutically acceptable salts and combinations thereof.

4 . The method of claim 1 , wherein the emulsifying agent is sorbitan monooleate.

5 . The method of claim 1 , wherein the composition is administered at least once per day.

6 . The method of claim 1 , wherein the JAK/STAT inhibitor is tofacitinib or a pharmaceutically acceptable salt thereof.

7 . The method of claim 1 , wherein the composition further comprises a solvent.

Assignments (2)
SECURITY INTEREST Recorded Dec 10, 2025
From: MADAME RX, LLC D/B/A CHEMISTRY RX
To: DEERPATH FUND SERVICES, LLC, AS AGENT
Reel/Frame 073173/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2022
From: BRICHTA, LARS
To: CHEMISTRY RX
Reel/Frame 059955/0079 →
Continuity (2)
Provisional Application 62680054 · Jun 4, 2018
Related Publication 20210213021A1 · Jul 15, 2021
References Cited (58)
US 20080280838A1 · Cho et al. · 2008 [cited by applicant]
US 20110130706A1 · Kellogg et al. · 2011 [cited by applicant]
US 20110130711A1 · Lederman et al. · 2011 [cited by applicant]
US 20110130748A1 · Kellogg et al. · 2011 [cited by applicant]
US 20110212167A1 · Ali · 2011 [cited by applicant]
US 20120259311A1 · Hirshberg · 2012 [cited by applicant]
US 20140065153A1 · Christiano · 2014 [cited by examiner]
US 20140276359A1 · Alvarez · 2014 [cited by applicant]
US 20150284405A1 · Trzupek et al. · 2015 [cited by applicant]
US 20170095621A1 · Hirshberg · 2017 [cited by applicant]
US 20170174772A1 · Nirula · 2017 [cited by examiner]
US 20170224760A1 · Garruto et al. · 2017 [cited by applicant]
US 20180193320A1 · Kaupinen · 2018 [cited by applicant]
US 20180289772A1 · Song · 2018 [cited by applicant]
US 20190231782A1 · Chen · 2019 [cited by examiner]
US 20200038338A1 · Wambier et al. · 2020 [cited by applicant]
US 20200101000A1 · Cotsarelis et al. · 2020 [cited by applicant]
US 20210353600A1 · Brichta · 2021 [cited by applicant]
US 20210353622A1 · Brichta · 2021 [cited by applicant]
BR 102018069553 · 2020 [cited by applicant]
EP 3695832 · 2020 [cited by applicant]
WO 1991007431 · 1991 [cited by applicant]
WO 1994027594 · 1994 [cited by applicant]
WO WO2010036947 · 2010 [cited by applicant]
WO WO2011082235 · 2011 [cited by applicant]
WO WO2012061537 · 2012 [cited by applicant]
WO WO2012106249 · 2012 [cited by applicant]
WO WO2013149194 · 2013 [cited by applicant]
WO WO2016179605 · 2016 [cited by applicant]
WO 2018042352A1 · 2018 [cited by applicant]
WO WO2019138291 · 2019 [cited by applicant]
WO WO2019152232 · 2019 [cited by applicant]
WO WO2019232242 · 2019 [cited by applicant]
WO WO2019236596 · 2019 [cited by applicant]
WO WO2020046820 · 2020 [cited by applicant]
WO WO2020136650 · 2020 [cited by applicant]
WO WO2021240163 · 2021 [cited by applicant]
Lee, Ji Su, et al. “Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib.” Journal of Dermatological Treatment 29.8 (2018): 819-822. (Year: 2018). [cited by examiner]
Cheng, Michelle W., et al. “Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.” Journal of drugs in dermatology: JDD 17.7 (2018): 800-803. (Year: 2018). [cited by examiner]
Dhayalan, Arjun, and Brett A. King. “Tofacitinib citrate for the treatment of nail dystrophy associated with alopecia universalis.” JAMA dermatology 152.4 (2016): 492-493. (Year: 2016). [cited by examiner]
U.S. Appl. No. 17/302,781, filed May 12, 2021. [cited by applicant]
European Extended Search Report for European No. 19815877.6 dated Jul. 14, 2022, 15 pages. [cited by applicant]
International Search Report and Written Opinion dated Aug. 26, 2021 for International Application No. PCT/US2021/070540, 9 pages. [cited by applicant]
International Search Report and Written Opinion dated Aug. 26, 2021 for International Application No. PCT/US2021/070539, 7 pages. [cited by applicant]
International Search Report and Written Opinion dated Sep. 16, 2019 for International Application No. PCT/US2019/035415, 13 pages. [cited by applicant]
Indian Hearing Objections dated Oct. 20, 2022 for Indian Patent Application No. 202027057073, 9 pages. [cited by applicant]
Bay Art, Cheryl B. et al., “Topical Janus Kinase Inhibitors for the Treatment of Pediatric Alopecia Areata”, Journal of the American Academy of Dermatology, 2017, 77.1: 167-170, dated Dec. 31, 2017. [cited by applicant]
Contin et al., “Male Androgenetic Alopecia Treated with Microneedling Alone or Associated with Injectable Minoxidil by Microinfusion of Drugs into the Skin.” Jun. 3, 2016, 4 pages. [cited by applicant]
Dha Y Alan, Aijun et al, “Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated with Alopecia Universalis”, JAMA Dermatology, 2016, 152.4: 492-493, dated Dec. 31, 2016. [cited by applicant]
Dhurat et al., “A Randomized Evaluator Blinded Study of Effect of Microneedling in Androgentic Alopeica: A Piot Study.” Jan.-Mar. 2013, 10 pages. [cited by applicant]
Gentile et al., “Regenerative Biotechnologies in Plastic Surgery: A Multicentric, Retrospective, Case-Series Study on the Use of Micro-Needling with Low-Level Light/Laser Therapy as a Hair Growth Boost in Patients Affec… [cited by applicant]
Kim et al., The Skin-Permeation-Enhancing Effect of Phosphatidylcholine: Caffeine as a Model Active Ingredient. Journal of Cosmetic Science. 53. 363-74. (Year: 2002). [cited by applicant]
Sengupta et al. (2016). Improved Skin Penetration. AAPA PharmSciTech, vol. 17, No. 2, Apr. 2016. (Year: 2016). [cited by applicant]
“MilliporeSigma. Poloxamer 188 Solution”, Web page, <https://www.sigmaaldrich.com/US/en/product/sigma/p5556?gclid=Cj0KCQjw8uOWBhDXARlsAOxKJ2HXo8yt61Awput19pfVX9T7GZGSxT8VS28oysxTV9DmPrCgxtHkDlaAkJ3EALw_wcB (Year: 2022)>… [cited by applicant]
“Topical Tacrolimus”, Web page <https://www.medicaljournals.se/acta/download/10.1080/000155502320624203/>, “Topical Tacrolimus (FK506): Treatment Failure in Four Cases of Alopecia Universalis”, 2 pages, accessed on Aug.… [cited by applicant]
“Treatment of Alopecia”, Web page <https://www.applications.emro.who.int/imemrf/J_Pak_Assoc_Dermatol/J_Pak_Assoc_Dermatol_2015_25_3_197_201.pdf>, “Efficacy of Topical Tacrolimus 0.1% and Clobetasol Propionate 0.05% in t… [cited by applicant]
Office Action issued in Japanese Patent Application No. 2020-568468, Jun. 20, 2023, pp. 5. [cited by applicant]
Chetyl et al., Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata, Journal of the American Academy of Dermatology, Jul. 2017, vol. 77, No. 1, pp. 167-170. https://doi.org/10.1016/j.jaad.2017.… [cited by applicant]